...
首页> 外文期刊>Journal of pharmacological sciences. >Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling.
【24h】

Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling.

机译:压力和血管反应:丝裂原激活的蛋白激酶和激活蛋白1作为有希望的血管重塑治疗靶标。

获取原文
获取原文并翻译 | 示例

摘要

Mitogen-activated protein kinases (MAP kinases), including extracellular signal-regulated kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38, play a central role in cellular responses by various stress stimuli such as cell proliferation, apoptosis, migration, or gene expression. Furthermore, activator protein-1 (AP-1), a transcription factor which can be activated by MAP kinases, also is involved in a variety of celllar responses, as well as MAP kinases. MAP kinases and AP-1 are significantly activated in vascular tissues by hypertension, angiotensin II, or balloon injury. We have made dominant negative mutants of MAP kinases or c-Jun, to specifically inhibit in vivo activation of MAP kinases or AP-1. Vascular gene transfer of each dominant negative mutant of MAP kinases or c-Jun prevents intimal hyperplasia after balloon injury, which is associated with the inhibition of smooth muscle cell proliferation in the intima and the media and probably also associated with inhibition of smooth muscle cell migration. However, in vitro findings on cultured vascular smooth muscle cells suggest that the molecular mechanism underlying inhibition of intimal hyperplasia may be different among each dominant negative mutant of MAP kinases and c-Jun. MAP kinases and c-Jun seem to be the promising therapeutic target for vascular remodeling.
机译:丝裂原激活的蛋白激酶(MAP激酶),包括细胞外信号调节激酶(ERK),c-Jun NH(2)-末端激酶(JNK)和p38,在各种应激刺激的细胞反应中起着核心作用,例如细胞增殖,凋亡,迁移或基因表达。此外,激活蛋白1(AP-1),一种可以被MAP激酶激活的转录因子,也参与了各种细胞应答以及MAP激酶。高血压,血管紧张素II或球囊损伤可在血管组织中显着激活MAP激酶和AP-1。我们已经制作了MAP激酶或c-Jun的显性负突变体,以特异性抑制MAP激酶或AP-1的体内激活。 MAP激酶或c-Jun的每个显性负突变体的血管基因转移可防止球囊损伤后的内膜增生,这与抑制内膜和培养基中平滑肌细胞的增殖有关,也可能与抑制平滑肌细胞的迁移有关。但是,在体外培养的血管平滑肌细胞上的发现表明,抑制内膜增生的分子机制可能在MAP激酶和c-Jun的每个显性负突变体之间都不同。 MAP激酶和c-Jun似乎是有希望的血管重塑治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号